The emergence of drugs like copyright and Semaglutide signifies a major shift in how we manage blood sugar. These innovative therapies belong to a class known as GLP-1 target agonists, which mimic the effects of a natural hormone that controls glucose levels and hunger. First, developed for diabetic conditions, their effectiveness in facilitating f